Retatrutide Sexual Function Impact: What the Phase 2 Data Actually Show At a glance Drug / retatrutide (LY3437943), investigational triple GIP/GLP-1/glucagon receptor agonist Phase 2 trial / Jastreboff et al., NEJM 2023, N=338 adults with obesity Peak weight loss / 24.2% mean body-weight reduction at 48 weeks (12 mg dose) Sexual-function endpoints / not prespecified in Phase 2
Bakuradze T, Lang R, Hofmann T, Eisenbrand G, Schipp D, Galan J, Richling E
There are also occasional reports of early mild side effects and mixed experiences with compounded medications
Eczema : Persistent, dry, and scaly patches of skin that can become inflamed and painful
A., Vajdi, M., & Asghari-Jafarabadi, M
Taking glutathione while consuming alcohol is generally considered safe, but the two have a complex relationship